Juluca® is ViiV Healthcare’s first 2-drug regimen, once-daily, single-pill that combines the integrase strand transfer inhibitor (INSTI) dolutegravir, with the non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine.
Juluca® was approved by the US Food and Drug Administration (FDA) on 21st November 2017 and is indicated as a complete regimen for the maintenance treatment of HIV-1 infection in adults who are virologically suppressed on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of Juluca¹. Juluca® will allow patients to reduce the number of antiretrovirals (ARVs) that they take, whilst maintaining the efficacy of traditional three-drug regimens in a small, single-pill regimen.¹,2